SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into securities purchase agreements for a private investment in public equity financing that is expected to result in gross proceeds of approximately $140.0 million, before deducting placement agent fees and other expenses..

新加坡和美国新泽西州北不伦瑞克和中国杭州，2026年2月3日（环球新闻网）-- Adlai Nortye Ltd.（纳斯达克：ANL）（“公司”或“Adlai Nortye”），一家专注于开发创新癌症疗法的临床阶段生物技术公司，今天宣布已达成证券购买协议，进行一项预计在扣除配售代理费用和其他开支前总收益约为1.4亿美元的私募股权投资公开股权融资。

In the private placement, the Company is selling 64,615,386 Class A ordinary shares of the Company (equivalent of 21,538,462 American Depositary Shares, each representing 3 Class A ordinary shares), at a price of $2.1667 per Class A ordinary shares (equivalent of $6.50 per ADS).

在私募配售中，公司以每股2.1667美元的价格（相当于每份美国存托凭证6.50美元）出售64,615,386股公司A类普通股（相当于21,538,462份美国存托凭证，每份代表3股A类普通股）。

The private placement was co-led by Cormorant Asset Management and Columbia Threadneedle Investments with participation from both new and existing investors including Balyasny Asset Management L.P., Point72, Squadron Capital Management and Casdin Capital.

私募股权融资由 Cormorant Asset Management 和 Columbia Threadneedle Investments 联合领投，新老投资者共同参与，包括 Balyasny Asset Management L.P.、Point72、Squadron Capital Management 和 Casdin Capital。

The private placement includes the sale of approximately $55 million of Class A ordinary Shares to the entities controlled by Yang Lu, Chairman and Chief Executive Officer of the Company.

私募配售包括向公司董事长兼首席执行官杨露控制的实体出售约5500万美元的A类普通股。

“We are pleased that this high-quality healthcare investor group came together to support Adlai Nortye and our innovative and potentially best-in-class RAS-targeting therapies,” said Yang Lu, Chairman and Chief Executive Officer of Adlai Nortye. “We thank the investors for their confidence in the broad potential of our RAS-targeting therapies and Next-generation cancer immunotherapies, and their support for our mission to transform deadly cancer into a chronic and eventually curable disease.”.

“我们很高兴这个高质量的医疗投资者团体能够联合起来支持Adlai Nortye以及我们创新的、潜在同类最佳的RAS靶向疗法，” Adlai Nortye董事长兼首席执行官杨鲁表示，“我们感谢投资者对我们RAS靶向疗法和下一代癌症免疫疗法广泛潜力的信任，并支持我们将致命癌症转化为慢性病并最终可治愈的使命。”

Jefferies, Leerink Partners, Lucid Capital Markets, H.C. Wainwright & Co. and Jones are acting as joint placement agents for the private placement.

Jefferies、Leerink Partners、Lucid Capital Markets、H.C. Wainwright & Co. 和 Jones 担任此次私募的联合配售代理。

The securities being issued and sold in this private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements.

本次私募发行和出售的证券尚未根据修订后的《1933年证券法》或适用的州证券法进行注册，除非依据有效的注册声明或适用的注册要求豁免，否则不得在美国境内发售或出售。

Adlai Nortye has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the ADSs issued in the private placement..

阿德莱·诺泰已同意向证券交易委员会提交一份注册声明，以注册在私募中发行的美国存托股份（ADS）的转售。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售或征求购买本文所述任何证券的要约，且在任何州或司法管辖区，不得在根据该州或司法管辖区的证券法进行注册或资格认证之前，进行此类证券的出售、要约或征求，因为此类行为可能属违法。

About

关于

Adlai Nortye

阿德莱·诺泰

Adlai Nortye is a global clinical-stage company at the forefront of discovering and developing innovative cancer therapies. Leveraging its dual R&D presence in the United States and China, Adlai Nortye is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a significant difference.

Adlai Nortye是一家全球临床阶段的公司，处于发现和开发创新癌症疗法的前沿。凭借其在美国和中国的双重研发优势，Adlai Nortye正在构建一个强大的候选药物管道，专注于它认为可以产生重大影响的两个关键领域。

(1) Next-generation cancer immunotherapies: Adlai Nortye’s drug candidates, AN8025 (a tri-functional fusion protein of αPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

下一代癌症免疫疗法：Adlai Nortye公司的药物候选物AN8025（一种三功能融合蛋白αPD-L1 x CD86变体 x LAG3变体）和AN4005（一类首创的口服小分子PD-L1抑制剂），旨在以新颖的方式激活癌症免疫。

(2) RAS-targeting therapies: Adlai Nortye is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors..

(2) RAS靶向疗法：Adlai Nortye公司正在通过AN9025（一种口服的泛RAS(ON)抑制剂）和AN4035（一种靶向CEACAM5的ADC，将强效的泛RAS(ON)抑制剂直接递送至肿瘤）来应对RAS驱动的癌症。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的谨慎声明

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

本新闻稿包含经修订的1933年《证券法》第27A条和经修订的1934年《证券交易法》第21E条所指的前瞻性陈述。在某些情况下，您可以通过诸如“目标”、“预期”、“假设”、“相信”、“考虑”、“继续”、“可能”、“设计”、“由于”、“估计”、“期望”、“目的”、“打算”、“可能”、“目标”、“计划”、“定位”、“潜力”、“预测”、“寻求”、“应该”、“针对”、“将”、“会”等术语以及其他类似的表达来识别前瞻性陈述，这些表达预示或表明未来事件和趋势，或这些术语的否定形式或其他类似术语。

All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the expected closing date of the private placement; cash operating runway; and the intended use of proceeds.

本新闻稿中包含的所有非历史事实的陈述均为前瞻性陈述。这些前瞻性陈述包括但不限于以下内容：私募预计完成日期、现金运营跑道以及所得款项的预期用途。

These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Annual Report on Form 20-F and earnings release on Form 6-K and the Company’s other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release.

这些风险及其他风险在公司年度报告 Form 20-F 中标题为“风险因素”的章节以及 Form 6-K 上的收益发布和公司向美国证券交易委员会提交的其他文件中有更详细的描述。公司在此新闻稿中做出的任何前瞻性声明均依据经修订的《1995 年私人证券诉讼改革法案》发布，且仅截至本新闻稿发布之日有效。

Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise..

除非法律要求，公司不承担公开更新任何前瞻性陈述的义务，无论是由于新信息、未来事件或其他原因。

Company contact:

公司联系人：

Investor Relations

投资者关系

Email: ir@adlainortye.com

电子邮件：ir@adlainortye.com